JP2016536327A - 関節リウマチの治療における、又は、鎮痛剤としての使用のための抗体中和ｇｍ−ｃｓｆ - Google Patents

関節リウマチの治療における、又は、鎮痛剤としての使用のための抗体中和ｇｍ−ｃｓｆ Download PDF

Info

Publication number
JP2016536327A
JP2016536327A JP2016537322A JP2016537322A JP2016536327A JP 2016536327 A JP2016536327 A JP 2016536327A JP 2016537322 A JP2016537322 A JP 2016537322A JP 2016537322 A JP2016537322 A JP 2016537322A JP 2016536327 A JP2016536327 A JP 2016536327A
Authority
JP
Japan
Prior art keywords
functional fragment
dose
neutralizing antibody
csf
primate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016537322A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016536327A5 (enExample
Inventor
ヴァーグナー トーマス
ヴァーグナー トーマス
カールソン マリン
カールソン マリン
シュタウム カルトフト マルギート
シュタウム カルトフト マルギート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Takeda GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda GmbH filed Critical Takeda GmbH
Publication of JP2016536327A publication Critical patent/JP2016536327A/ja
Publication of JP2016536327A5 publication Critical patent/JP2016536327A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2016537322A 2013-08-30 2014-09-01 関節リウマチの治療における、又は、鎮痛剤としての使用のための抗体中和ｇｍ−ｃｓｆ Pending JP2016536327A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361871904P 2013-08-30 2013-08-30
US201361871900P 2013-08-30 2013-08-30
US61/871,900 2013-08-30
US61/871,904 2013-08-30
PCT/EP2014/068489 WO2015028657A1 (en) 2013-08-30 2014-09-01 Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020042267A Division JP2020109108A (ja) 2013-08-30 2020-03-11 関節リウマチの治療における、又は、鎮痛剤としての使用のための抗体中和ｇｍ−ｃｓｆ

Publications (2)

Publication Number Publication Date
JP2016536327A true JP2016536327A (ja) 2016-11-24
JP2016536327A5 JP2016536327A5 (enExample) 2017-10-12

Family

ID=51454704

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016537322A Pending JP2016536327A (ja) 2013-08-30 2014-09-01 関節リウマチの治療における、又は、鎮痛剤としての使用のための抗体中和ｇｍ−ｃｓｆ
JP2020042267A Pending JP2020109108A (ja) 2013-08-30 2020-03-11 関節リウマチの治療における、又は、鎮痛剤としての使用のための抗体中和ｇｍ−ｃｓｆ
JP2022076303A Pending JP2022105160A (ja) 2013-08-30 2022-05-02 関節リウマチの治療における、又は、鎮痛剤としての使用のための抗体中和ｇｍ－ｃｓｆ
JP2024103720A Pending JP2024123249A (ja) 2013-08-30 2024-06-27 関節リウマチの治療における、又は、鎮痛剤としての使用のための抗体中和ｇｍ－ｃｓｆ

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020042267A Pending JP2020109108A (ja) 2013-08-30 2020-03-11 関節リウマチの治療における、又は、鎮痛剤としての使用のための抗体中和ｇｍ−ｃｓｆ
JP2022076303A Pending JP2022105160A (ja) 2013-08-30 2022-05-02 関節リウマチの治療における、又は、鎮痛剤としての使用のための抗体中和ｇｍ－ｃｓｆ
JP2024103720A Pending JP2024123249A (ja) 2013-08-30 2024-06-27 関節リウマチの治療における、又は、鎮痛剤としての使用のための抗体中和ｇｍ－ｃｓｆ

Country Status (12)

Country Link
US (2) US10745475B2 (enExample)
EP (2) EP3889178A1 (enExample)
JP (4) JP2016536327A (enExample)
KR (3) KR20240090993A (enExample)
CN (2) CN118178647A (enExample)
AU (3) AU2014314053C1 (enExample)
BR (1) BR112016003293A8 (enExample)
CA (1) CA2922251C (enExample)
ES (1) ES2860480T3 (enExample)
MX (2) MX385854B (enExample)
RU (1) RU2714919C2 (enExample)
WO (1) WO2015028657A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2517718B1 (en) 2003-05-15 2016-03-02 Ampio Pharmaceuticals, Inc. Treatment of T-cell mediated diseases
EA028343B1 (ru) 2011-10-10 2017-11-30 Ампио Фармасьютикалз, Инк. Лечение дегенеративного заболевания сустава
RU2736513C2 (ru) 2014-08-18 2020-11-17 Ампио Фармасьютикалз, Инк. Лечение патологических состояний суставов
EP3310375A4 (en) 2015-06-22 2019-02-20 Ampio Pharmaceuticals, Inc. USE OF LOW-MOLECULAR FRACTIONS OF HUMAN SERUMALBUMINE IN THE TREATMENT OF ILLNESSES
SG11201901789WA (en) * 2016-09-19 2019-03-28 I Mab Anti-gm-csf antibodies and uses thereof
CN107840885B (zh) * 2016-09-19 2020-11-10 天境生物科技(上海)有限公司 Gm-csf抗体及其用途
KR20200012823A (ko) 2017-02-01 2020-02-05 예일 유니버시티 이뇨제 내성의 치료
EP3735421A4 (en) 2018-01-05 2021-09-22 Corvidia Therapeutics, Inc. METHOD OF TREATMENT OF IL-6 MEDIATED INFLAMMATION WITHOUT IMMUNSUPPRESSION
EP3765630B1 (en) * 2018-03-14 2024-08-28 Indiana University Research And Technology Corporation Precision medicine for pain: diagnostic biomarkers, pharmacogenomics, and repurposed drugs

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008536505A (ja) * 2005-04-18 2008-09-11 マイクロメット アクツィエン ゲゼルシャフト ヒト顆粒球マクロファージコロニー刺激因子の抗体中和剤
JP2011518886A (ja) * 2008-04-28 2011-06-30 カロバイオス ファーマシューティカルズ インコーポレイティッド 顆粒球−マクロファージコロニー刺激因子に対する抗体

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2916711A1 (de) 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
US4783441A (en) 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
JPS59147297A (ja) 1983-02-10 1984-08-23 株式会社日立製作所 原子炉圧力容器の耐震構造
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0158487B1 (en) 1984-04-09 1991-08-28 Takeda Chemical Industries, Ltd. Stable composition of interleukin-2
GB8624899D0 (en) 1986-10-17 1986-11-19 Sandoz Ltd Monoclonal antibodies
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5070013A (en) 1988-05-31 1991-12-03 Schering Corporation Immunochemical assay for human granulocyte-macrophage colony stimulating factor
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
WO1994009149A1 (en) 1990-08-10 1994-04-28 Amrad Corporation Limited Monoclonal antibody
CA2060741A1 (en) 1991-02-11 1992-08-12 Robert S. Greenfield Gm-csf inhibiting oligopeptides
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US6309636B1 (en) 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
ES2434840T3 (es) 1995-07-27 2013-12-17 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US7112324B1 (en) 1998-04-21 2006-09-26 Micromet Ag CD 19×CD3 specific polypeptides and uses thereof
US7101551B2 (en) 2000-02-14 2006-09-05 Mitsubishi Pharma Corporation Remedies for hepatitis C
US20050271663A1 (en) 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
MXPA04000747A (es) 2001-07-25 2004-07-08 Protein Desing Labs Inc Formulacion farmaceutica liofilizada estable de anticuerpos igg.
IL161677A0 (en) 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
JP2006500905A (ja) 2002-02-13 2006-01-12 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ヒト化ｇｍ−ｃｓｆ抗体
SI1478394T1 (sl) 2002-02-27 2008-12-31 Immunex Corp STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
WO2004042009A2 (en) 2002-10-30 2004-05-21 Genentech, Inc. Inhibition of il-17 production
AU2005249360B2 (en) 2004-04-12 2011-07-21 Medimmune, Llc Anti-IL-9 antibody formulations and uses thereof
ATE435238T1 (de) 2004-05-05 2009-07-15 Micromet Ag Herstellung eines einkettigen fv antikörperfragments
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20060177436A1 (en) 2004-12-16 2006-08-10 Genentech, Inc. Methods for Treating Autoimmune Disorders
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
RU2447085C2 (ru) 2005-05-18 2012-04-10 МорфоСис АГ Анти-gm-csf антитела и их применение
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
CA2638811A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
US7741450B2 (en) 2006-02-08 2010-06-22 Morphotek Inc. Antibodies to GM-CSF
MX2008012291A (es) 2006-03-27 2009-01-12 Medimmune Ltd Miembro que enlaza al receptor gm-csf.
EP2101780B1 (en) * 2006-11-21 2013-10-09 Kalobios Pharmaceuticals, Inc. Methods of treating chronic inflammatory diseases using a gm-csf antagonist
EP2170268A2 (en) 2007-06-25 2010-04-07 Amgen, Inc. Compositions of specific binding agents to hepatocyte growth factor
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
CN104072613A (zh) 2007-11-13 2014-10-01 Evec股份有限公司 与hGM-CSF结合的单克隆抗体及包含它的药物组合物
CA2717987C (en) 2008-04-29 2018-11-13 Micromet Ag Inhibitors of gm-csf and il-17 for therapy
CA2747206C (en) 2008-12-22 2018-04-24 The University Of Melbourne Pain treatment
US20120116059A1 (en) 2009-05-05 2012-05-10 Morphosys Ag Treatment For M Treatment For Multiple Sclerosis
EP2458990B1 (en) 2009-07-28 2016-03-30 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
BR112012013148A2 (pt) 2009-12-29 2017-03-21 F Hoffmann - La Roche Ag formulação farmacêutica e uso
EP3409289B1 (en) 2010-02-26 2020-09-30 Novo Nordisk A/S Stable antibody containing compositions
EP2399604A1 (en) 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
CA2851322C (en) * 2011-10-10 2020-03-31 Medimmune Limited Treatment for rheumatoid arthritis with gm csfr alpha antibodies
MA37946B1 (fr) * 2012-09-20 2018-09-28 Morphosys Ag Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
WO2014068029A1 (en) 2012-10-31 2014-05-08 Takeda Gmbh Lyophilized formulation comprising gm-csf neutralizing compound
JP6346389B1 (ja) 2016-08-03 2018-06-20 古河電気工業株式会社 金属粒子含有組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008536505A (ja) * 2005-04-18 2008-09-11 マイクロメット アクツィエン ゲゼルシャフト ヒト顆粒球マクロファージコロニー刺激因子の抗体中和剤
JP2011518886A (ja) * 2008-04-28 2011-06-30 カロバイオス ファーマシューティカルズ インコーポレイティッド 顆粒球−マクロファージコロニー刺激因子に対する抗体

Also Published As

Publication number Publication date
AU2020203917A1 (en) 2020-07-02
AU2014314053C1 (en) 2023-11-02
US20210171620A1 (en) 2021-06-10
JP2024123249A (ja) 2024-09-10
KR20240090993A (ko) 2024-06-21
US11795216B2 (en) 2023-10-24
JP2022105160A (ja) 2022-07-12
EP3039039A1 (en) 2016-07-06
MX385854B (es) 2025-03-18
KR20220045064A (ko) 2022-04-12
WO2015028657A1 (en) 2015-03-05
JP2020109108A (ja) 2020-07-16
BR112016003293A8 (pt) 2022-08-16
US20160355584A1 (en) 2016-12-08
RU2016109944A3 (enExample) 2018-07-09
KR20160044035A (ko) 2016-04-22
RU2714919C2 (ru) 2020-02-21
AU2014314053B2 (en) 2020-03-12
MX2021010472A (es) 2021-10-01
CN118178647A (zh) 2024-06-14
CA2922251A1 (en) 2015-03-05
AU2014314053A1 (en) 2016-02-11
BR112016003293A2 (pt) 2017-11-21
CA2922251C (en) 2023-10-17
RU2016109944A (ru) 2017-10-06
EP3039039B1 (en) 2021-03-10
MX2016002177A (es) 2016-06-28
AU2023210647A1 (en) 2023-10-12
CN105705518A (zh) 2016-06-22
ES2860480T3 (es) 2021-10-05
US10745475B2 (en) 2020-08-18
EP3889178A1 (en) 2021-10-06

Similar Documents

Publication Publication Date Title
US11795216B2 (en) Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
TWI618543B (zh) Ｉｌ-１７抗體用於製備治療強直性脊椎炎之藥物之用途
JP5905534B2 (ja) 多発性硬化症を治療する方法
JP6657089B2 (ja) 関節リウマチを治療するための組成物およびこれを使用する方法
KR20150048887A (ko) Ｉｌ-4ｒ 길항제 투여로 아토피성 피부염을 치료하는 방법
EP3191120B1 (en) Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients
US20150291689A1 (en) Compositions and Methods for Treating Rheumatoid Arthritis
AU2022200690B2 (en) Method of treating tendinopathy using interleukin-17 (IL-17) antagonists
WO2025045766A1 (en) Compositions comprising humanized anti-cd40 antibodies and methods for treating rheumatoid arthritis using the same
HK40062612A (en) Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics
AU2014259526B2 (en) Methods of treating ankylosing spondylitis using IL-17 antagonists
HK40110169A (en) Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170828

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170828

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180806

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190514

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190902

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191111